The Filing Desk

Ironwood Pharmaceuticals

IRWD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IRWD · Last close · November 13, 2026
$4.83
Value Ironwood Pharmaceuticals yourself

Ironwood Pharmaceuticals' revenue fell 15.7% to $296 million in fiscal 2025. Its operating margin was 33.3%, up from 26.5% a year earlier. Free cash flow was $127 million, up 22.8%. The diluted share count rose 1.8%.

IRONWOOD PHARMACEUTICALS INC Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001104659-26-020489 Updated
Revenue
$296M
15.7%
Operating margin
33.3%
6.8 pts
Net income
$24M
2629.2%
Free cash flow
$127M
22.8%
Return on equity
—
 
Market cap
$812M
Nov 13 close
P/E
5.4x
On $0.90 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ironwood Pharmaceuticals does

Ironwood Pharmaceuticals is a biotechnology company focused on digestive (gastrointestinal) and rare diseases. Its only commercial product is LINZESS (linaclotide), the first approved drug in a class of digestive medicines called GC-C agonists. In the U.S. it treats irritable bowel syndrome with constipation and chronic constipation in adults, and some constipation in children. It is also sold in Mexico, Japan and China, and as CONSTELLA in Canada and parts of Europe.

Ironwood does not sell linaclotide worldwide by itself. It has partners: AbbVie in the U.S. and most other countries, AstraZeneca in China and Astellas in Japan.

Its main drug in development is apraglutide, a long-acting injected peptide for short bowel syndrome patients who depend on intravenous nutrition. It came with the June 2023 purchase of VectivBio. In 2025 the FDA told Ironwood it needs a confirmatory Phase III trial, called STARS-2, before it can seek approval. Ironwood was incorporated in Delaware in 1998 as Microbia.

Its biggest risks, as it describes them

  • Apraglutide may not win regulatory approval, and a further Phase III trial is needed first.
  • Delays in clinical testing could raise costs and delay revenue.
  • It depends on one commercial product, LINZESS, sold mostly through partners.
  • The VectivBio purchase increases its exposure to doing business in foreign countries.
  • It may be unable to keep the benefits of orphan drug designation, including market exclusivity.
From Ironwood Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2019 to 2025, earnings per share grew 1.2% a year and net income 1.9% a year, as new shares raised the share count by 4% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments6206569289216
Debt incl. finance leases454396398——
Net debt (negative means net cash)−166−260306——
Net debt to EBITDA−0.7x−1.0x———
Debt to equity0.8x0.6x———
Interest coverage7.5x33.0x−43.7x2.8x3.0x
Current ratio4.6x30.6x0.8x4.7x1.1x
Quick ratio4.6x30.6x0.8x4.7x1.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ironwood Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Ironwood Pharmaceuticals reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 8——
Rule of 4049.2%8.8%27.2%
Altman Z''−26.28−11.79−11.97
Accruals ratio−150.9%−25.0%−27.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFail——
Current ratio roseFailPassFail
Share count didn't risePassFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score4 of 8——
Companies that report no gross profit are scored on the other eight.

Compare

Put Ironwood Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———
EvolusFY2511.6%−11.0%−15.4%−47.2%—2Compare
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7Compare
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7Compare
Aurinia PharmaceuticalsFY2520.4%37.1%47.8%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue274298347428390414411443351296
Revenue growth83.2%8.9%16.2%23.6%−9.1%6.2%−0.8%7.8%−20.6%−15.7%
Gross profit272279314404386—————
Research and development1408810111588704411611195
Operating income−52−15−151120143232250−9459398
Net income−82−117−28222106528175−1,002124
Diluted EPS (US$)−0.56−0.78−1.850.140.663.210.96−6.450.010.15
Diluted shares (millions)145149153156161164186155160163
Cash flow
Cash from operations−26−101−7111169262274183104127
Capital expenditure4307200000
Free cash flow−30−104−714167262274183103127
Dividends paid0000000000
Share buybacks0000024126000
Acquisitions100000000000
Stock-based compensation29314031312227323017
Balance sheet at fiscal year end
Cash and short-term investments54221—1773636206569289216
Debt incl. finance leases—147148—430454396398——
Total assets7106063324035591,1271,100471351397
Total liabilities643596528496497521448817652659
Shareholders' equity6710−196−9363606652−346−301−262
Margins and ratios
Gross margin99.3%93.6%90.5%94.4%99.2%—————
Operating margin−18.9%−5.2%−43.5%28.0%36.7%56.1%61.0%−213.5%26.5%33.3%
Net margin−29.8%−39.2%−81.5%5.0%27.3%127.7%42.6%−226.4%0.2%8.1%
Free cash flow margin−11.0%−34.7%−20.6%0.8%42.9%63.2%66.6%41.4%29.4%42.9%
Rule of 40 (growth + FCF margin)72.2%−25.8%−4.3%24.4%33.8%69.5%65.9%49.2%8.8%27.2%
Return on capital—————81.5%41.7%−424.6%——
Return on equity−101.0%−305.5%———158.1%27.8%−654.9%——
Return on assets−12.3%−17.8%−60.2%5.8%22.1%62.7%15.7%−127.5%0.2%6.4%
Net debt to EBITDA————0.5x−0.7x−1.0x———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ironwood Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ironwood Pharmaceuticals.